Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and Rituximab in Relapsed/Refractory CLL
NCT00949988Phase 2Terminated
- Sponsor
- University of California, San Diego
- Start
- May 2009
- Primary completion
- Apr 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of dasatinib in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by University of California, San Diego. Primary endpoints: Dose-limiting Toxicities and Maximum Tolerated Dose at 1 year. Started May 2009; status: terminated.
02
Drugs
dasatinib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00949988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00949988.